Dopamine-agonist combination therapy for improving sleep quality
The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.
1. A method of treating a patient suffering from restless-leg syndrome or periodic-limb-movement disorder, comprising the step of administering a single dosage form consisting of:
(a) one or more pharmaceutically acceptable carriers;
(b) eszopiclone;
(c) a dopamine-receptor agonist selected from the group consisting of amantadine, apomorphine, bromocriptine, cabergoline, carmoxirole, dopexamine, fenoldopam, ibopamine, lergotrile, lisuride, memantine, mesulergine, pergolide, piribedil, pramipexole, quinagolide, ropinirole, roxindole, and talipexole or a pharmaceutically acceptable salt of any of them; and
(d) optionally, a coating.
2. The method of claim 1 , wherein said dopamine-receptor agonist is selected from the group consisting of apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, and ropinirole or a pharmaceutically acceptable salt of any of them.